개요
세계 항오심제 시장은 2023년 23억 달러에 달할 것으로 예상되며, 2024-2031년 예측 기간 동안 CAGR 6.2%로 성장하여 2031년에는 37억 달러에 달할 것으로 예상됩니다.
항오심제는 제토제로도 알려져 있으며, 메스꺼움과 구토를 예방하거나 완화하는 데 도움이 됩니다. 이 두 가지 증상은 다양한 질병, 치료, 시술 및 약물에 의해 유발될 수 있습니다. 구토는 위나 장의 유해 물질을 배출하기 위한 신체의 방어 반사로 여겨지지만, 특히 심한 탈수 증상이 있는 경우 구토를 억제하기 위해 구토제를 복용해야 하는 경우가 종종 있습니다.
이러한 약물은 멀미, 화학요법으로 인한 메스꺼움 및 구토, 수술 후 메스꺼움 및 구토와 같은 증상을 치료하는 데 주로 사용됩니다. 이 시장은 암과 위장염의 유병률 증가, 연구개발 활동의 급증 등의 요인에 의해 주도되고 있습니다.
촉진요인
암과 위장염의 유병률 증가
세계 항오심제 시장의 수요는 여러 요인에 의해 주도되고 있습니다. 시장을 촉진하는 주요 요인 중 하나는 암 발병률의 증가이며, 화학요법의 증가는 항오심제 시장의 주요 촉진제입니다. 화학요법으로 인한 메스꺼움과 구토(CINV)는 일반적인 부작용이며, 이를 관리하기 위해서는 구토 방지제를 사용해야 합니다.
2023년 7월 NIH 발표에 따르면, 성인 암 환자의 약 70-80%가 화학요법 유발성 메스꺼움과 구토(CINV)를 경험하고 있으며, CINV는 여전히 암 치료와 관련된 가장 고통스러운 증상 중 하나이며, 화학요법 순응도 저하와 관련이 있다고 합니다.
또한, 전 세계적으로 위장염의 높은 유병률도 구토제 수요에 기여하고 있습니다. 위장염 치료는 메스꺼움과 구토의 부작용을 동반하는 것으로 알려져 있습니다. 항오심제는 치료 중 이러한 부작용을 조절하는 데 유용합니다.
또한, 주요 기업의 인식 제고 프로그램 및 의약품 승인은 이 지역의 시장 성장을 촉진할 것으로 보입니다. 예를 들어, 2023년 10월 아스텔라스제약은 유럽종양학회(ESMO) 2023년 학술대회에서 연구 결과를 발표했습니다. 이 발표에서 회사는 페럿의 위 손상과 구토 빈도에 대한 구토 방지제의 효과에 초점을 맞춘 연제를 발표했습니다.
또한 2022년 4월, Evoke Pharma, Inc.는 미국 식품의약국(FDA)으로부터 Gimoti(메토클로프라미드) 비강 점안제 신약의 독점 판매권을 획득했습니다. 이로써 에보크는 해치 왁스만법에 따라 제네릭 의약품의 경쟁으로부터 제품을 보호하기 위해 최초 승인일로부터 3년간 독점 판매권을 획득했습니다. 메토클로프라미드는 도파민 길항제로 강력한 구토억제제로 사용되고 있습니다.
억제요인
약물 관련 부작용, 개인 인식 부족, 사용 가능한 치료 방법의 제한, 엄격한 규제 요건 등의 요인이 시장을 저해할 것으로 예상됩니다.
이 보고서에 대한 자세한 정보 - 샘플 요청
Overview
The global antinauseant drugs market reached US$ 2.3 billion in 2023 and is expected to reach US$ 3.7 billion by 2031 growing with a CAGR of 6.2% during the forecast period 2024-2031.
Antinauseants, also known as antiemetics, help prevent or alleviate nausea and vomiting. These two symptoms are prevalent and can be caused by many different conditions, therapies, procedures, and medications. Though vomiting is considered to be a protective reflex of the body to expel toxic substances in the stomach and gut, antiemetic drugs are often necessary to suppress vomiting, especially if there's severe dehydration.
These drugs are often used to treat conditions such as motion sickness, chemotherapy-induced nausea and vomiting, and postoperative nausea and vomiting. The market is driven by factors such as the rising prevalence of cancer and gastroenteritis and the surge in research and development activities.
Market Dynamics: Drivers
Rising prevalence of cancer and gastroenteritis
The demand for the global antinauseant drugs market is driven by multiple factors. One of the primary factors driving the market is the rising incidence of cancer and the increase in chemotherapy treatments are major drivers of the antinauseant drugs market. Chemotherapy-induced nausea and vomiting (CINV) is a common side effect that requires the use of antiemetic medications to manage.
According to the NIH publication in July 2023, about 70% to 80% of adults with cancer experience chemotherapy-induced nausea and vomiting (CINV). CINV remains one of the most distressing symptoms associated with cancer therapy and is associated with decreased adherence to chemotherapy.
Similarly, the high prevalence of gastroenteritis globally is also contributing to the demand for antiemetic drugs. Gastroenteritis treatments have witnessed several adverse effects of nausea and vomiting. Antiemetic drugs are useful for controlling such side effects during treatments.
Moreover, key players' awareness programs and drug approvals would propel this market growth in this region. For instance, in October 2023, Astellas Pharma Inc. presented research results at the European Society for Medical Oncology (ESMO) Congress 2023. During this presentation, the company also presented an abstract focusing on the effects of antiemetics on gastric injury and emesis frequency in ferrets.
Also, in April 2022, Evoke Pharma, Inc., was granted new drug product exclusivity by the U.S. Food and Drug Administration (FDA) for Gimoti (metoclopramide) nasal spray. Evoke now has exclusive marketing privileges over three years from the initial date of approval under the Hatch-Waxman Act to protect the product from generic drug competition. Metoclopramide is a dopamine antagonist that is used as a potent antiemetic drug.
Restraints
Factors such as the adverse effects associated with the drugs, lack of awareness among individuals, limited treatment availability, and stringent regulatory requirements, are expected to hamper the market.
For more details on this report - Request for Sample
The global antinauseant drugs market is segmented based on drug type, application, distribution channels, and region.
The serotonin-receptor antagonists segment accounted for approximately 45.3% of the global antinauseant drugs market share
The serotonin-receptor antagonists segment is expected to hold the largest market share over the forecast period. 5HT3 antagonists are routinely used as antiemetics postoperatively and during chemotherapy. These include numerous launched products - azasetron, granisetron, indisetron, ondansetron, palonosetron, dolasetron, ramosetron, and tropisetron.
Moreover, key players in the industry drug launches & approvals, and awareness programs would drive this segment growth. For instance, in July 2024, Amneal Pharmaceuticals, Inc. announced the launch of FOCINVEZ, a ready-to-use injectable. Unlike other versions of fosaprepitant, this single-dose vial product is free of Polysorbate 80 does not require reconstitution or dilution, and can be administered directly from the vial using the included vial hanger.
Focinvez and Cinvanti are recommended for use in the treatment of acute and delayed nausea and vomiting, in combination with serotonin (5-HT3) receptor antagonists and a corticosteroid (usually dexamethasone). FOCINVEZ for injection is indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents.
According to the article published by the Canadian Institutes of Health Research in May 2022, Ondansetron, a 5-HT3 antagonist approved in Canada as an antiemetic. This drug is used for nausea and vomiting associated with chemotherapy and post-operation.
North America accounted for approximately 42.2% of the global antinauseant drugs market share.
North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence of cancer & chemotherapy-induced nausea and vomiting (CINV) and gastroenteritis in the U.S., which would propel this market growth in this region.
According to the American Cancer Society, in December 2023, around 609,820 cancer deaths and 1,958,310 new cancer cases are estimated to occur in the U.S. Thus, the prevalence of such diseases causing vomiting and nausea is anticipated to propel the market growth over the forecast period.
Moreover, key players in the industry strategies such as mergers & acquisitions and drug approvals would propel this market growth in this region. For instance, in January 2022, Cumberland Pharmaceuticals Inc. announced that it had entered into and closed on a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO (granisetron transdermal patch), from Kyowa Kirin, Inc. the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. SANCUSO is the first and only FDA-approved prescription patch for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment.
Also, in September 2022, Heron Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved APONVIE (aprepitant) injectable emulsion, for intravenous use for the prevention of postoperative nausea and vomiting (PONV) in adults.
The major global players in the antinauseants market include Heron Therapeutics, Inc., TAIHO PHARMACEUTICAL CO., LTD, Pfizer Inc., Merck & Co., Inc., GLENMARK PHARMACEUTICALS LTD, Amneal Pharmaceuticals LLC, Akums Drugs and Pharmaceuticals Ltd, Astellas Pharma Inc, EVOKE PHARMA, and Barhemsys.
The global antinauseants drug market report would provide approximately 62 tables, 57 figures, and 182 pages.
LIST NOT EXHAUSTIVE